Labeling Supplements FDA: Safety, Efficacy, and CBE Requirements
Labeling supplements to FDA are filed under different reporting categories depending on the type of change. Safety labeling changes (adding or strengthening warnings, adverse reactions, contraindications) are filed as CBE-0 supplements under 21 CFR 314.70(d). Efficacy labeling changes (new indications, dosing based on clinical data) require Prior Approval Supplements. All labeling must be submitted in Structured Product Labeling (SPL) format per 21 CFR 314.50(l), and the supplement must include both redlined and clean versions of the affected labeling sections.
Key Takeaways
Key Takeaways
- Safety labeling changes (adding/strengthening warnings, adverse reactions) are filed as CBE-0 supplements and can be implemented immediately upon filing.
- Efficacy labeling changes (new indications, dosing from clinical data) require Prior Approval Supplements with full FDA review before implementation.
- All labeling must be submitted in SPL format per 21 CFR 314.50(l), with both redlined and clean versions of affected sections.
- ANDA holders are expected to maintain labeling consistent with the Reference Listed Drug for all non-carved-out content.
Types of Labeling Changes
The Three Categories
FDA labeling changes for approved drugs fall into three broad categories, each with different regulatory pathways:
| Category | Change Type | Filing Mechanism | FDA Approval Before Implementation |
|---|---|---|---|
| Safety labeling changes | Adding/strengthening safety information | CBE-0 (most), some CBE-30 | No |
| Efficacy labeling changes | New indication, dosing, clinical data claims | PAS (Efficacy Supplement) | Yes |
| Administrative/editorial changes | Typographical corrections, format updates, NDC changes | CBE-0 or Annual Report | No |
Regulatory Basis
The filing requirements for labeling changes come from multiple regulatory provisions:
| Provision | What It Covers |
|---|---|
| 21 CFR 314.70(b) | Labeling changes requiring PAS (efficacy supplements) |
| 21 CFR 314.70(c) | Labeling changes requiring CBE-30 |
| 21 CFR 314.70(d) | Labeling changes eligible for CBE-0 |
| Section 505(o)(4), FD&C Act | FDA authority to require labeling changes (FDAAA 2007) |
| 21 CFR 201 | General labeling requirements |
| 21 CFR 208 | Medication Guide requirements |
| 21 CFR 314.50(l) | SPL format requirement |
Safety Labeling Changes via CBE-0
What Qualifies as a Safety Labeling Change
Safety labeling changes are modifications to the prescribing information that add or strengthen safety-related content. Under 21 CFR 314.70(d)(2), the following changes may be made via CBE-0:
| Change Type | CFR Reference | Examples |
|---|---|---|
| Add or strengthen a contraindication | 314.70(d)(2)(i) | Adding a new contraindication based on post-marketing case reports |
| Add or strengthen a warning or precaution | 314.70(d)(2)(ii) | Upgrading a precaution to a boxed warning based on new data |
| Add or strengthen an adverse reaction | 314.70(d)(2)(iii) | Adding a newly identified adverse reaction from FAERS data |
| Add or strengthen dosage and administration for safety | 314.70(d)(2)(iv) | Adding renal dose adjustment based on post-marketing renal failure reports |
| Add or strengthen statements about drug abuse/dependence | 314.70(d)(2)(v) | Strengthening abuse potential language based on post-marketing reports |
| Delete false, misleading, or unsupported claims | 314.70(d)(2)(vi) | Removing an indication not supported by adequate evidence |
The Obligation to Update Proactively
FDA expects applicants to actively monitor safety data and update labeling proactively. Under 21 CFR 201.57(c)(6)(i), labeling must include adverse reactions from both clinical trials and post-marketing experience. The applicant is responsible for ensuring labeling reflects current knowledge about the product's safety profile.
The FDAAA 2007 strengthened this obligation through Section 505(o)(4), which gives FDA explicit authority to require labeling changes. However, the expectation is that applicants will identify the need for safety labeling changes before FDA issues an order.
Sections of the Prescribing Information Affected
The FDA-approved prescribing information follows the Physician Labeling Rule (PLR) format per 21 CFR 201.56 and 201.57. The sections most commonly affected by safety labeling changes:
| Section | PLR Section Number | Common CBE-0 Changes |
|---|---|---|
| Highlights | N/A (summary section) | Updated warnings, boxed warning, new adverse reactions |
| Boxed Warning | 201.57(c)(1) | Addition of new boxed warning or strengthening existing |
| Indications and Usage | 201.57(c)(2) | Deletion of unsupported indication |
| Dosage and Administration | 201.57(c)(3) | Safety-related dose adjustments |
| Contraindications | 201.57(c)(4) | New contraindication |
| Warnings and Precautions | 201.57(c)(5) | New or strengthened warnings |
| Adverse Reactions | 201.57(c)(6) | New adverse reactions from post-marketing experience |
| Drug Interactions | 201.57(c)(7) | Newly identified drug interactions |
| Use in Specific Populations | 201.57(c)(8) | New safety data for pregnancy, pediatric, renal/hepatic impairment |
| Overdosage | 201.57(c)(10) | Updated overdose management |
| Patient Counseling Information | 201.57(c)(18) | Updated safety counseling points |
How to File a Safety Labeling CBE-0
Step 1: Identify the trigger. Document the source of the new safety information (FAERS data, literature report, PMR study results, foreign regulatory action, etc.).
Step 2: Draft labeling revisions. Prepare redlined and clean versions of all affected sections. The redlined version must clearly show exactly what text is being added, deleted, or modified.
Step 3: Prepare the SPL file. Per 21 CFR 314.50(l), all labeling must be submitted in Structured Product Labeling (SPL) format using Health Level Seven (HL7) standards. The SPL file is an XML document that contains the full prescribing information in a structured, machine-readable format.
Step 4: Prepare Module 1 documents. Include:
- Cover letter identifying this as a CBE-0 supplement for a safety labeling change
- FDA Form 356h
- Redlined labeling (showing changes)
- Clean labeling (final version)
- SPL file
- Rationale for the labeling change, including a summary of the safety data supporting the change
Step 5: Submit as an eCTD sequence. Submit as a new sequence in the application's eCTD lifecycle with submission type "Supplement" and sub-type "CBE-0."
Step 6: Implement immediately. Upon filing, begin distributing product with the updated labeling.
FDA Review of Safety Labeling CBE-0
After receiving the CBE-0, FDA reviews the proposed labeling changes. Several outcomes are possible:
| Outcome | Description | Applicant Action |
|---|---|---|
| Acceptance | FDA agrees with the labeling changes as submitted | Continue distributing with updated labeling |
| Modification request | FDA agrees the change is needed but requests different wording | Submit revised labeling per FDA request |
| Additional changes requested | FDA identifies other labeling sections that should also be updated | Submit additional CBE-0 with requested changes |
| Rejection (rare) | FDA determines the change is not supported or is inappropriate | Negotiate with FDA; may need to revert labeling |
Efficacy Supplements (PAS for Labeling)
What Requires an Efficacy Supplement
Any labeling change that adds or modifies effectiveness claims requires a PAS, classified by FDA as an Efficacy Supplement (SE). These include:
| Change | Example | Data Required |
|---|---|---|
| New indication | Adding "treatment of moderate-to-severe psoriasis" to an existing RA indication | Phase III clinical trials |
| New patient population | Adding pediatric indication | Pediatric clinical studies (PREA or voluntary) |
| New dosing regimen based on efficacy data | Adding once-daily dosing option based on PK/PD study | Clinical pharmacology and efficacy data |
| Expanded indication | Broadening "mild" to "mild-to-moderate" disease | Additional clinical evidence |
| New clinical pharmacology claims | Adding pharmacogenomic dosing guidance | Clinical pharmacology study data |
Content of an Efficacy Supplement
Efficacy supplements are substantially more complex than safety labeling supplements:
| Module | Content for Efficacy Supplement |
|---|---|
| Module 1 | Cover letter, Form 356h, proposed labeling (redlined and clean), SPL, patent/exclusivity information |
| Module 2.5 | Clinical Overview summarizing the clinical development program for the new indication |
| Module 2.7 | Clinical Summary including summaries of biopharmaceutic, clinical pharmacology, efficacy, and safety studies |
| Module 5 | Clinical Study Reports per ICH E3 format, integrated summaries of safety and efficacy |
Review Timeline for Efficacy Supplements
| Review Type | PDUFA Goal | When Used |
|---|---|---|
| Standard Review | 10 months from submission | Most efficacy supplements |
| Priority Review | 6 months from submission | Supplements for serious conditions with unmet need |
Labeling Negotiation for Efficacy Supplements
During review, FDA's Division of Labeling and Nonprescription Drug Products works with the review division to finalize the proposed labeling. Common negotiation points include:
- Wording of the Indications and Usage section
- Specific claims allowed in the Clinical Studies section
- Dosage and Administration instructions
- Limitations of use
- Content of the Highlights section
The applicant should expect iterative labeling discussions during the review cycle. FDA typically proposes labeling language near the end of review, and the applicant has limited time to respond.
CBE-30 Labeling Changes
When CBE-30 Applies to Labeling
CBE-30 is less commonly used for labeling changes, but it applies in certain situations:
| Scenario | Example |
|---|---|
| Labeling change to add information about a drug interaction based on a newly conducted in vivo study | Adding a new drug interaction warning based on a dedicated PK interaction study, where the interaction is clinically significant but not immediately safety-critical |
| Labeling changes reflecting newly approved CMC changes | Updating the Description section to reflect a new formulation approved via CBE-30 |
| Changes to Patient Package Insert content (when not safety-critical) | Updating patient information leaflet with new administration instructions |
CBE-30 vs. CBE-0 for Labeling: The Key Distinction
The distinction between CBE-0 and CBE-30 for labeling changes centers on urgency and safety impact:
| Factor | CBE-0 | CBE-30 |
|---|---|---|
| Safety urgency | Immediate patient safety concern | Important but not immediately urgent |
| Nature of change | Adding/strengthening safety information | Other labeling modifications |
| Implementation timing | Immediate | After 30-day waiting period |
| Typical use | New adverse reaction, contraindication, warning | Non-urgent informational updates |
SPL Format Requirements
What Is SPL?
Structured Product Labeling (SPL) is an XML-based standard for the electronic submission and distribution of drug labeling. FDA requires all labeling submitted with supplements to be in SPL format per 21 CFR 314.50(l)(1)(i).
SPL uses the Health Level Seven (HL7) Clinical Document Architecture (CDA) standard. The SPL file contains the complete prescribing information in a structured format that allows:
- Machine-readable content for DailyMed and other databases
- Structured extraction of safety information
- Automated comparison of labeling versions
- Integration with clinical decision support systems
SPL Document Structure
| SPL Element | Content |
|---|---|
| Document ID | Unique identifier for the SPL document |
| Set ID | Identifier that remains constant across versions of the same labeling |
| Version Number | Increments with each labeling revision |
| Effective Time | Date the labeling version becomes effective |
| Sections | Organized by PLR section (Boxed Warning, Indications, Dosage, etc.) |
| Data Elements | Drug name, active ingredients, inactive ingredients, route, dosage form, NDC codes |
SPL Submission Requirements
| Requirement | Details |
|---|---|
| Initial SPL | Submitted with original NDA/ANDA/BLA |
| Updated SPL | Required with every labeling supplement (PAS, CBE-30, CBE-0) |
| DailyMed listing | FDA transmits approved SPL to DailyMed for public display |
| Format validation | SPL must pass FDA's SPL validation tool |
| Content sections | Must match PLR format per 21 CFR 201.56/201.57 |
Common SPL Errors
| Error | Consequence | Prevention |
|---|---|---|
| Mismatched Set ID | Creates duplicate product listing in DailyMed | Maintain consistent Set ID across all labeling versions |
| Incorrect version number | Version tracking breaks | Increment version number with each submission |
| Missing sections | SPL validation failure | Include all required PLR sections even if unchanged |
| NDC code errors | Product identification errors in pharmacy systems | Verify NDC codes against FDA NDC Directory |
| Invalid XML syntax | Submission rejected at gateway | Validate XML before submission |
Labeling Review Process at FDA
Pre-Submission Considerations
Before filing a labeling supplement, applicants should consider:
- Is the change data-driven? FDA expects labeling changes to be supported by evidence. For safety changes, this means adverse event data, literature, or study results. For efficacy changes, this means clinical trial data.
- Does the change affect other labeling sections? A change to Warnings and Precautions may require corresponding changes to Adverse Reactions, Patient Counseling Information, and the Highlights section. Incomplete cross-referencing is a common deficiency.
- Is the change consistent with the current PLR format? Labeling that has not been converted to PLR format may require additional formatting work alongside the content change.
- Will the change affect the Medication Guide? If a Medication Guide exists for the product, safety labeling changes typically require corresponding Medication Guide updates.
FDA's Labeling Review Process
| Stage | Activities | Timeline |
|---|---|---|
| Receipt | FDA acknowledges receipt of the supplement | Days |
| Clinical review | Medical officer reviews the safety or efficacy data supporting the change | Weeks to months |
| Labeling review | Division of Labeling reviews the proposed language | Concurrent with clinical review |
| Cross-disciplinary review | Pharmacology, statistics, and other disciplines review as needed | Concurrent |
| Labeling negotiation | FDA and applicant discuss final wording | Late in the review cycle |
| Action | FDA approves, requests modifications, or issues CRL | Per PDUFA timeline |
REMS Labeling Changes
When REMS Affects Labeling
Products with a Risk Evaluation and Mitigation Strategy (REMS) have additional labeling considerations:
| REMS Element | Labeling Impact |
|---|---|
| Medication Guide | Product labeling must reference the Medication Guide; changes to the REMS may require Medication Guide updates |
| Communication Plan | Healthcare provider communication materials must be consistent with approved labeling |
| ETASU | Labeling may reference ETASU requirements (e.g., "available only through a restricted program") |
| REMS modification | Changes to the REMS often require corresponding labeling changes |
Filing REMS-Related Labeling Changes
REMS modifications and their associated labeling changes are submitted as supplements. The supplement type depends on the nature of the change:
| Change | Filing Type |
|---|---|
| Modification to Medication Guide for safety reasons | CBE-0 (safety labeling) + REMS modification |
| Addition of new ETASU | PAS (REMS modification requires FDA approval) |
| Modification of Communication Plan | CBE-30 or PAS depending on significance |
| REMS-related labeling that adds new safety information | CBE-0 |
ANDA Labeling Considerations
The Labeling Carve-Out
ANDA holders must generally adopt the labeling of the Reference Listed Drug (RLD). However, there are specific situations where ANDA labeling may differ:
| Situation | ANDA Labeling Action |
|---|---|
| RLD updates safety labeling | ANDA holder must update labeling accordingly, typically via CBE-0 |
| RLD adds new indication | ANDA holder may carve out the new indication if it is protected by patent or exclusivity |
| RLD labeling includes method-of-use patent | ANDA holder carves out the patented indication (Section viii carve-out) |
| RLD has REMS | ANDA holder must adopt shared REMS or develop equivalent REMS |
Section viii Patent Carve-Out
Under 21 CFR 314.94(a)(8)(iv), an ANDA applicant may omit from its labeling an indication that is protected by a method-of-use patent listed in the Orange Book. The ANDA's labeling will differ from the RLD's labeling in the Indications and Usage section. When the patent expires, the ANDA holder must update labeling to include the previously carved-out indication.
Timing of ANDA Labeling Updates
When the RLD's labeling changes, ANDA holders are expected to update their labeling promptly. FDA does not specify an exact timeframe, but regulatory expectations are:
- Safety labeling changes: Update via CBE-0 as soon as practicable (within weeks of the RLD change)
- Non-safety labeling changes: Update at the next supplement submission or within a reasonable period
Labeling for Biologics (BLA)
Biosimilar Labeling
Biosimilar labeling follows specific FDA guidance (Labeling for Biosimilar Products, July 2018). Key differences from traditional generic labeling:
| Element | Biosimilar Approach |
|---|---|
| Nonproprietary name | Core name plus FDA-designated suffix |
| Indications | May include all approved indications of the reference product unless carved out |
| Clinical studies section | Includes biosimilar-specific study data |
| Interchangeability | If designated, stated in labeling |
| Immunogenicity | Biosimilar-specific immunogenicity data included |
BLA Labeling Supplements
BLA holders follow 21 CFR 601.12 for labeling supplements. The framework mirrors 314.70 but applies to biological products:
| Change | BLA Filing |
|---|---|
| Safety labeling change | CBE-0 (21 CFR 601.12(d)) |
| New indication (efficacy supplement) | PAS (21 CFR 601.12(b)) |
| Administrative labeling change | CBE-0 or annual report |
Key Regulatory References
| Reference | Description |
|---|---|
| 21 CFR 201.56 | Content requirements for prescription drug labeling |
| 21 CFR 201.57 | Specific requirements for prescription drug labeling (PLR) |
| 21 CFR 208 | Medication Guide requirements |
| 21 CFR 314.50(l) | SPL format requirements |
| 21 CFR 314.70(b)-(d) | Supplement types for labeling changes |
| 21 CFR 314.94(a)(8)(iv) | ANDA labeling carve-out |
| 21 CFR 601.12 | BLA supplement requirements |
| Section 505(o)(4), FD&C Act | FDA authority to require labeling changes |
| FDA Guidance: Safety Labeling Changes (Jul 2013) | Implementation of Section 505(o)(4) |
| FDA Guidance: Labeling for Biosimilar Products (Jul 2018) | Biosimilar-specific labeling |
| FDA Guidance: SPL Implementation Guide | Technical SPL formatting requirements |
| PLR Final Rule (Jan 2006) | Physician Labeling Rule establishing current format |
| ICH M2 | Electronic standards for regulatory information |
References
Yes, in limited circumstances. ANDA labeling may differ from the RLD when the ANDA holder has carved out a patent-protected indication under Section viii. ANDA labeling may also temporarily differ if the RLD recently made a change that the ANDA holder has not yet implemented. However, FDA expects ANDA holders to maintain labeling consistent with the RLD for all non-carved-out content.